Targovax ASA - Additional information prior to the Extraordinary General Meeting

01 Mar 2023 07:00 CET

Oslo, Norway, 1 March 2023: Reference is made to Targovax ASA's ("Targovax" or
the "Company") stock exchange announcement on 16 February 2023 where the Company
called for an extraordinary general meeting (EGM) to be held at the Company's
offices at Lysaker on 9 March 2023 at 10:00 CET for the purpose of approving the
investment agreement for up to NOK 300m in convertible bonds with Atlas Special
Opportunities, LLC ("Atlas").

Important and relevant parts of the Investment and Subscription Agreement with
Atlas has been published on the Company's website:
https://www.targovax.com/en/extraordinary-general-meeting-2023/ and is also
attached to this notice.

A webcast presentation with a Q&A regarding the Atlas convertible bond facility
was held 28 February 2023. A recording of the presentation and the presentation
material is available on our web site on the following link:
https://www.targovax.com/en/presentations/.

Attachment: Atlas investment Agreement Public
Terms (https://mb.cision.com/Public/17093/3725461/9751250818e84b14.pdf)

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and to bring benefit to
cancer patients with few available treatment alternatives. Targovax is
developing its product candidates in different cancer indications, including
melanoma, mesothelioma, multiple myeloma and pancreatic cancer.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system against the tumor. ONCOS-102 has
demonstrated a favorable efficacy, immunological and safety profile in several
indications, both as monotherapy and in combinations, and ONCOS-102 is
progressing into a randomized phase 2 trial in melanoma patients resistant to PD
-1 checkpoint inhibitor treatment.

Targovax has also established a cutting-edge circular RNA (circRNA) program with
the intent to develop next generation RNA therapeutics for various applications,
building on clinical experience and deep mechanistic insights from its first
generation products.  In addition, Targovax has a KRAS immunotherapy program,
with lead candidate TG01 due to enter clinical trials in an enhanced format in
pancreatic cancer and multiple myeloma during early 2023. This provides Targovax
with a rich pipeline of innovative future therapeutic candidates to follow ONCOS
-102.

More information:
Access the news on Oslo Bors NewsWeb site

583936_Atlas_investment_Agreement_Public_Terms.pdf